home / stock / zgnx / zgnx news

ZGNX News and Press, Zogenix Inc. From 11/07/18

Stock Information
Company Name: Zogenix Inc.
Stock Symbol: ZGNX
Market: NASDAQ
Website: zogenix.com
Menu
ZGNX ZGNX Quote ZGNX Short ZGNX News ZGNX Articles ZGNX Message Board
Get ZGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ZGNX - Notable earnings after Thursday's close

AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
ZGNX - Zogenix to Present at Stifel 2018 Healthcare Conference

EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive...

ZGNX - Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8

EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September...

ZGNX - Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees. The ...
ZGNX - Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executiv...

Previous 10 Next 10